利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.025 秒)

    Administration of acemannan
    2.
    发明授权
    Administration of acemannan 失效
    行政管理

    公开(公告)号：US5106616A

    公开(公告)日：1992-04-21

    申请号：US229164

    申请日：1988-08-05

    申请人： Bill H. McAnalley ,  Robert H. Carpenter ,  Harley R. McDaniel

    发明人： Bill H. McAnalley ,  Robert H. Carpenter ,  Harley R. McDaniel

    IPC分类号： A61K39/39 ,  A61K31/715 ,  A61K31/736 ,  A61K36/00 ,  A61K36/886 ,  A61K36/896 ,  A61P1/04 ,  A61P1/12 ,  A61P35/00 ,  A61P37/00 ,  A61P37/04 ,  A61P43/00 ,  C07H15/24 ,  C08B37/00 ,  C12N7/00

    CPC分类号： C08B37/0087 ,  A61K31/715 ,  A61K31/736 ,  A61K36/886 ,  A61K39/39 ,  C07H15/24 ,  C08B37/00 ,  C12N7/00 ,  A61K2039/55583 ,  C12N2720/10011 ,  C12N2760/18411 ,  Y10S514/885

    摘要： Acemannan has now been discovered to be a potent inducer of Interleukin 1 (Il-1) and prostaglandin E.sub.2 (PGE.sub.2) production by human peripheral blood adherent cells in culture. Il-1 has been shown to be an important macrophage product and is associated with influencing the activity and production of T lymphocytes, fibroblasts, B lymphocytes and endothelial cells. Acemannan has no demonstrated toxicity, and acts as an adjuvant and immunoenhancer. Administration of an amount of acemannan sufficient to stimulate monocytes and macrophages not only produces Il-1 and PGE.sub.2 but also stimulates phagocytosis, increases antibody production, enhances antiviral activity in the serum and, in those patients with AIDS/ARC, produces defective HIV virus.Acemannan has been shown to affect the rate of virus production in viral vaccine master seed cultures by accelerating the rate of viral replication. In addition, acemannan is a potent adjuvant to viral vaccines in chickens. Acemannan has also shown specific antitumor activity against sarcoid tumors in horses.

    摘要翻译： Acemannan现已被发现是培养物中人外周血粘附细胞产生的白介素1（Il-1）和前列腺素E2（PGE2）的有效诱导剂。 已证实Il-1是重要的巨噬细胞产物，与影响T淋巴细胞，成纤维细胞，B淋巴细胞和内皮细胞的活性和产生有关。 Acemannan没有证明有毒性，作为佐剂和免疫增强剂。 施用足以刺激单核细胞和巨噬细胞的量的acemannan不仅产生Il-1和PGE2，而且还刺激吞噬作用，增加抗体产生，增强血清中的抗病毒活性，并且在AIDS / ARC患者中产生有缺陷的HIV病毒。 Acemannan已显示通过加速病毒复制速率来影响病毒疫苗大师种子培养物中的病毒生产速率。 此外，acemannan是鸡中病毒疫苗的有效佐剂。 Acemannan还显示出针对马的结节肿瘤的特异性抗肿瘤活性。

    MODULATION OF SPHINGOSINE 1-PHOSPHATE METABOLIZING ENZYMES FOR THE TREATMENT OF NEGATIVE-STRAND RNA VIRUS INFECTIONS
    4.
    发明申请
    MODULATION OF SPHINGOSINE 1-PHOSPHATE METABOLIZING ENZYMES FOR THE TREATMENT OF NEGATIVE-STRAND RNA VIRUS INFECTIONS 有权
    用于治疗负面病毒RNA病毒感染的磷脂酸1-磷酸酯代谢酶的调节

    公开(公告)号：US20150126564A1

    公开(公告)日：2015-05-07

    申请号：US14122399

    申请日：2012-05-31

    申请人： THE CURATORS OF THE UNIVERSITY OF MISSOURI

    发明人： Bumsuk Hahm ,  Young-Jin Seo ,  Stephen Alexander ,  Vijayan Madhuvanthi

    IPC分类号： A61K31/426 ,  A61K31/133

    CPC分类号： A61K31/426 ,  A61K31/133 ,  A61K48/005 ,  C12N9/88 ,  C12N15/113 ,  C12N15/1137 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2760/16111 ,  C12N2760/18411 ,  C12Y401/02027

    摘要： The present invention relates to compounds and methods for the prevention or treatment of infections by negative strand RNA viruses, such as influenza virus and measles virus, wherein said compounds delay or inhibit viral replication by modulating the level or activity of a polypeptide involved in the synthesis or degradation of sphingosine-1-phosphate (S1P) in a cell, tissue, or subject. The methods involve administration of one or more compounds which modulate the level of gene expression, where the gene encodes a polypeptide involved in regulating the metabolic level of S1P, or modulate the level or activity of a polypeptide involved in regulating the metabolic level of S1P, such as sphingosine kinase (SK) and S1P lyase (SPL). Exemplary methods are directed towards reducing the level of SW by reducing the level or activity of one or more SKs, increasing the level or activity of one or more SPLs, or a combination of both steps.

    摘要翻译： 本发明涉及通过负链RNA病毒如流感病毒和麻疹病毒预防或治疗感染的化合物和方法，其中所述化合物通过调节涉及合成的多肽的水平或活性延迟或抑制病毒复制 或降解细胞，组织或受试者中的鞘氨醇-1-磷酸（S1P）。 所述方法包括施用一种或多种调节基因表达水平的化合物，其中基因编码参与调节S1P代谢水平的多肽，或调节涉及调节S1P代谢水平的多肽的水平或活性， 如鞘氨醇激酶（SK）和S1P裂解酶（SPL）。 示例性方法旨在通过降低一个或多个SK的水平或活动，增加一个或多个SPL的水平或活动或两个步骤的组合来降低SW的水平。